Imcyse
Imcyse develops active targeted immunotherapies to treat and cure severe chronic diseases caused by disruptions of the immune system.
The company’s unique active immunotherapy technology platform works to destroy locally the immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™; specific modified peptides, allowing for the generation of a new type of T-cell, called cytolytics CD4 T cells. The long-term effects of the Imcyse approach help to prevent and treat diseases with no current therapeutic alternative and to cure the patient without impairing their immune defense.
Imcyse develops active targeted immunotherapies to treat and cure severe chronic diseases caused by disruptions of the immune system.
The company’s unique active immunotherapy technology platform works to destroy locally the immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™; specific modified peptides, allowing for the generation of a new type of T-cell, called cytolytics CD4 T cells. The long-term effects of the Imcyse approach help to prevent and treat diseases with no current therapeutic alternative and to cure the patient without impairing their immune defense.